Last reviewed 2026-05-13 · How we verify

SBRT+PD-1 Inhibitor + Chemotherapy

SBRT+PD-1 Inhibitor + Chemotherapy is a Immune checkpoint inhibitor + Chemotherapy Small molecule drug developed by West China Hospital. It is currently in Phase 3 development for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.

This combination therapy uses Stereotactic Body Radiation Therapy (SBRT) to target cancer cells, while also inhibiting the PD-1 receptor to enhance the immune response and reduce tumor growth, and chemotherapy to kill rapidly dividing cancer cells.

This combination therapy uses Stereotactic Body Radiation Therapy (SBRT) to target cancer cells, while also inhibiting the PD-1 receptor to enhance the immune response and reduce tumor growth, and chemotherapy to kill rapidly dividing cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.

At a glance

Mechanism of action

SBRT delivers high doses of radiation to specific areas of the body, minimizing damage to surrounding healthy tissue. PD-1 inhibitors, such as those in this combination, work by blocking the PD-1 receptor on T cells, allowing them to recognize and attack cancer cells more effectively. Chemotherapy is used to target rapidly dividing cancer cells and slow tumor growth.

Approved indications

• Metastatic non-small cell lung cancer, PD-L1 positive
• Metastatic melanoma

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Rash
• Pneumonitis

Key clinical trials

• HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
• SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC (PHASE3)
• Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer (PHASE2)
• Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer (PHASE2)
• Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. (PHASE1, PHASE2)
• A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC (PHASE2)
• Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma (PHASE2)
• Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• SBRT+PD-1 Inhibitor + Chemotherapy CI brief — competitive landscape report
• SBRT+PD-1 Inhibitor + Chemotherapy updates RSS · CI watch RSS
• West China Hospital portfolio CI

Frequently asked questions about SBRT+PD-1 Inhibitor + Chemotherapy

Related

• Drug class: All Immune checkpoint inhibitor + Chemotherapy drugs
• Target: All drugs targeting PD-1
• Manufacturer: West China Hospital — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Metastatic non-small cell lung cancer, PD-L1 positive
• Indication: Drugs for Metastatic melanoma